Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOOST cells before or after birth for severe osteogenesis imperfecta
NL-OMON59222Phase 2Active, not recruiting
- Sponsor
- Karolinska Institutet
- Start
- Feb 2021
- Countries
- 1
01
Overview
Phase 2, open-label trial in Osteogenesis imperfecta type III and osteogenesis imperfecta type 4 (OI-IV) (2 arms), sponsored by Karolinska Institutet. Primary endpoint: Treatment-related adverse events. Started Feb 2021; status: active, not recruiting.
02
Conditions
Osteogenesis imperfecta type IIIosteogenesis imperfecta type 4 (OI-IV)
Beyond the preview
Go deeper on NL-OMON59222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59222.